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Endothelial injury is assumed to play a key role in the initiation and progression of 
both native coronary artery disease (CAD) and cardiac allograft vasculopathy (CAV) 
[1, 2]. Biochemical surrogate biomarkers of endothelial injury (e.g. von Willebrand 
factor, soluble thrombomodulin, soluble vascular cell adhesion molecule, soluble 
intercellular adhesion molecule, and soluble E-selectin) do not discriminate between 
endothelial activation and irreversible endothelial damage and lack endothelial 
specificity [3]. In contrast, cellular biomarkers of endothelial injury (circulating 
endothelial microparticles (CEMPs) and circulating endothelial cells (CECs)) are 
endothelial-specific. Microparticles are 0.1 µm to 1 µm large membrane vesicles that 
are released following cell activation or apoptosis [4]. In contrast to CEMPs, CECs 
constitute a parameter of irreversible damage of the endothelium [5, 6, 7]. CECs are 
mature endothelial cells that originate by detachment from the endothelial monolayer 
as a result of an endothelial insult. Thus, by combined quantification of CEMPs and 
CECs, it is possible to evaluate to which extent endothelial injury represents 
endothelial activation or endothelial denudation. We investigated whether a distinct 
pattern of endothelial injury (endothelial activation versus endothelial denudation) is 
observed in native CAD and CAV. 
Eighty patients with clinically stable native coronary artery disease (CAD) and thirty 
heart transplant recipients with cardiac allograft vasculopathy (CAV) were recruited 
in the current cross-sectional study. Stable native CAD patients were defined by the 
presence of at least one stenosis of 50% or more demonstrated by diagnostic coronary 
angiography. CAV was diagnosed in heart transplant recipients undergoing coronary 
angiography between 5 and 15 years after heart transplantation [8]. CAV was graded 
according to the ISHLT working formulation of a standardized nomenclature for 
CAV-2010 [9]. The study protocol conforms to the ethical guidelines of the 1975 
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Declaration of Helsinki as reflected by the a priori approval of the protocol by the 
Ethics Committee of the University Hospital Gasthuisberg. Written informed consent 
was obtained from all participants. The reference control group included 25 healthy 
control subjects (12 males and 13 females). Average age of healthy controls was 43.2 
± 2.0 years. 
Clinical characteristics, laboratory parameters, and medical therapy in patients with 
stable native CAD and heart transplant recipients with CAV are summarized in Table 
1. Patients with native CAD were 4.7 years (p<0.05) older, had a lower prevalence of 
hypertension (p<0.0001), and a higher body mass index than patients with CAV 
(p<0.05). C-reactive protein levels were 6.32-fold (p<0.001) higher in heart transplant 
recipients with CAV than in patients with native CAD. Lipoprotein levels were very 
similar and statin use was generalized in both conditions. The use of antiplatelet drugs 
was generalized in patients with native CAD and was restricted to one heart transplant 
recipient with CAV. 
The number of circulating endothelial cells, endothelial microparticles, and platelet 
microparticles was quantified by flow cytometry using a BD FACSCantoII flow 
cytometer and BD FACSDIVA software version 1.2.6 (BD Biosciences, San Jose, 
California, USA). The geometric mean of the concentration of circulating endothelial 
(CD45
- 
CD31
bright
 VEGFR-2
+
) cells (CECs) was 2.90-fold (p<0.001) and 2.34-fold 
(p<0.05) higher in patients with native CAD and with CAV, respectively, compared 
to healthy controls (data not shown). No significant difference of Annexin V negative 
CECs and of Annexin V positive (apoptotic) CECs was observed between patients 
with native CAD and transplant recipients with CAV. Taken together, the number of 
CECs as a parameter of irreversible endothelial damage is similarly increased in both 
types of arteriosclerosis. 
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Circulating endothelial (CD42a
-
 CD144
+
) microparticles (CEMPs), Annexin V 
negative CEMPs, and Annexin V positive CEMPs were elevated in patients with 
native CAD and transplant recipients with CAV compared to healthy controls as 
illustrated in Figure 1A, Figure 1B, and Figure 1C, respectively. The concentration of 
CEMPs (Figure 1A) and Annexin V negative CEMPs (Figure 1B) was 45.8% 
(p<0.01) and 59.2% (p<0.01) higher, respectively, in transplant recipients with CAV 
than in patients with native CAD. No significant difference in Annexin V positive 
CEMPs was observed between patients with native CAD and CAV (Figure 1C). 
Taken together, the selective increase of Annexin V negative CEMPs in transplant 
recipients with CAV compared to patients with native CAD is compatible with more 
pronounced endothelial cell activation in the former. 
Platelets can adhere to dysfunctional endothelium, exposed collagen, and 
macrophages, and promote initiation and progression of atherosclerosis [1, 10]. 
Platelet microparticles are a marker of platelet activation. We compared circulating 
platelet (CD61
+
) microparticles (CPMPs) in patients with native CAD and with CAV. 
Circulating platelet microparticles (CPMPs), Annexin V negative CPMPs, and 
Annexin V positive CPMPs were significantly lower in patients with native CAD 
compared to healthy controls and transplant recipients with CAV as illustrated in 
Figure 1D, Figure 1E, and Figure 1F, respectively. The median value of total CPMPs 
in patients with native CAD was 69.4% (p<0.001) and 71.6% (p<0.001) lower 
compared to healthy controls and transplant recipients with CAV, respectively. This 
decline was observed both for Annexin V negative CPMPs (Figure 1E) and Annexin 
V positive CPMPs (Figure 1F). No difference in any of these parameters was 
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observed between healthy controls and transplant recipients with CAV. Similar results 
were obtained when CD42a
+ 
CD31
+
 CPMPs were quantified (data not shown). 
Since all patients with native CAD and only one patient with CAV were taking 
antiplatelet drugs, this suggested that the observed difference in CPMPs is due to this 
class of medication. The concentration of CD61
+
 CPMPs (60.8/µl) in the CAV patient 
taking acetylsalicylic acid was in the order of magnitude of patients with native CAD. 
To further confirm the effect of acetylsalicylic acid on CPMPs, an additional 
quantification was performed in 11 heart transplant recipients taking this drug. The 
median value of CD61
+
 CPMPs (53.0/µl) in these heart transplant recipients was 
similar compared to patients with native CAD. 
In conclusion, the selective increase of Annexin V negative CEMPs and the absence 
of a difference in Annexin V positive CECs strongly suggest increased endothelial 
activation but not endothelial apoptosis in CAV positive patients compared to stable 
CAD patients. Use of antiplatelet drugs likely underlies the strikingly lower levels of 
CPMPs in patients with native CAD. 
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LEGEND TO THE FIGURE 
 
 
Figure 1. Individual value bar graphs illustrating a comparison between healthy 
controls (n=25), stable native CAD patients (n=80), and heart transplant 
recipients with CAV (n=30) of circulating endothelial microparticles (CEMPs) 
and of CD61
+ 
circulating platelet microparticles (CPMPs) Total CEMPs, Annexin 
V
-
 CEMPs, and Annexin V
+
 CEMPs are illustrated in panel A, B, and C, respectively. 
Horizontal lines in these three upper panels indicate the means. Total CD61
+ 
CPMPs, 
CD61
+ 
Annexin V
-
 CPMPs, and CD61
+ 
Annexin V
+
 CPMPs are shown in panel D, E, 
and F, respectively. Horizontal lines in these three lower panels indicate the medians. 
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Table 1. Clinical characteristics, laboratory parameters, and hypolipidemic and antiplatelet therapy in 
patients with stable native CAD and in transplant recipients with CAV. 
 Patients with stable 
native CAD 
(n=80) 
Patients with CAV 
(n=30) 
P value 
Age at inclusion in the study (years) 69.6 ± 1.2 64.9 ± 2.1 0.0459 
Sex (male/female) 63 (78.8%)/17 (21.3%) 24 (80.0%)/6 (20.0%) 1.00 
Current smoker (%) 7.5% 0% 0.186 
Hypertension (%) 47.5% 100% <0.0001 
Diabetes (%) 25.0% 36.7% 0.242 
Body mass index (kg/m
2
) 27.5 ± 0.6 25.5 ± 0.5 0.0337 
Platelet count (10
9
/L) 222 ± 5 217 ± 12 0.150 
Leukocyte count (10
9
/L) 7.19 ± 0.22 6.87 ± 0.24 0.398 
Monocyte count (10
9
/L) 0.435 ± 0.029 0.313 ± 0.039 0.012 
Lymphocyte count (10
9
/L) 1.94 ± 0.08 1.28 ± 0.12 <0.0001 
Neutrophil count (10
9
/L) 4.22 ± 0.20 3.78 ± 0.36 0.213 
Creatinine (mg/dl) 1.05 ± 0.03 1.60 ± 0.08 <0.0001 
CRP (mg/l) 1.95 ± 0.18 12.4 ± 3.3 <0.0001 
Cholesterol (mg/dl) 160 ± 4 156 ± 6 0.548 
Triglycerides (mg/dl) 132 ± 7 125 ± 12 0.557 
HDL cholesterol (mg/dl) 50.2 ± 1.8 54.2 ± 3.4 0.353 
Table(s)
LDL cholesterol (mg/dl) 83.6 ± 3.0 77.1 ± 4.0 0.402 
Acetylsalicylic acid (%) 88.8% 3.33% <0.0001 
Statins (%) 95.0% 100% 0.573 
Clopidogrel (%) 13.8% 0% 0.0334 
Data are expressed as means ± SEM for continuous variables. 
 
